STOCK TITAN

IDEAYA Biosciences (IDYA) teams with Roche on IDE892 and pan‑RAS combo in MTAP‑deleted pancreatic cancer

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

IDEAYA Biosciences reported a new clinical collaboration with Roche to study IDEAYA’s investigational PRMT5 inhibitor IDE892 with Roche’s pan-RAS inhibitor RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA will sponsor the trial and Roche will provide RG6505, with both companies retaining commercial rights to their respective drugs.

IDE892 is already in a Phase 1 dose-escalation trial in MTAP-deleted solid tumors, and IDEAYA plans Phase 1 combination cohorts in pancreatic cancer with RG6505 and in other tumors with its MAT2A inhibitor IDE397. The collaboration may also expand to a triplet regimen of IDE892, RG6505 and IDE397 under joint governance between the companies.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
MTAP deletion prevalence in PDAC up to 40% Estimated frequency of MTAP deletions in pancreatic ductal adenocarcinoma
IDE397 development stage Phase 2 MAT2A inhibitor used in planned combination and triplet regimens
IDE892 development stage Phase 1 Dose escalation trial in MTAP-deleted solid tumors
PRMT5 inhibitor medical
"IDE892, its investigational, potential best-in-class PRMT5 inhibitor"
A PRMT5 inhibitor is a drug that blocks the action of the enzyme PRMT5, which controls how some genes are turned on or off by tagging proteins inside cells. For investors, these drugs matter because they can slow or stop the growth of certain cancers and other diseases by reprogramming cell behavior, acting like a dimmer switch for disease-related genes; clinical trial results and approval decisions drive value and risk.
pan-RAS inhibitor medical
"in combination with Roche’s RG6505, a pan-RAS inhibitor"
A pan-RAS inhibitor is a drug designed to block activity of the RAS family of proteins (such as KRAS, NRAS and HRAS) that often drive uncontrolled cell growth in cancers. For investors, it matters because a single medicine that works across multiple RAS types can address a larger group of patients and reduce the risk that a tumor will bypass the drug, much like cutting power to several faulty switches instead of just one.
MTAP deletion medical
"in patients with pancreatic ductal adenocarcinoma that carry an MTAP deletion"
mtap deletion is the loss of the MTAP gene from a cell’s DNA, which can happen in some cancers. For investors, it matters because that genetic gap often creates a predictable weakness drugs can target, making affected tumors both a potential market for specialized therapies and a marker used by companies to select patients for trials; think of it as a missing bolt that lets a tailored tool work more effectively.
pancreatic ductal adenocarcinoma medical
"in patients with pancreatic ductal adenocarcinoma (“PDAC”) that carry an MTAP deletion"
A fast-growing cancer that starts in the cells lining the pancreas’ small ducts; it is the most common and aggressive form of pancreatic cancer. It matters to investors because its severity and limited treatment options drive high unmet medical need, large potential markets for effective drugs or diagnostics, and strong sensitivity of company valuations to clinical trial results, regulatory approvals, or changes in treatment guidelines—similar to how fixing a main leak can prevent major damage in a building.
MAT2A inhibitor medical
"with IDE397, the Company’s proprietary MAT2A inhibitor"
forward-looking statements regulatory
"Certain statements contained herein are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001676725 0001676725 2026-06-03 2026-06-03
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2026

 

 

IDEAYA Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38915   47-4268251

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

5000 Shoreline Court, Suite 300

South San Francisco, California 94080

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 443-6209

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   IDYA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 8.01

Other Events.

Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

On June 3, 2026, IDEAYA Biosciences, Inc. (the “Company”) announced it has entered into a clinical collaboration with F. Hoffmann-La Roche Ltd (“Roche”) to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class PRMT5 inhibitor, in combination with Roche’s RG6505, a pan-RAS inhibitor, in patients with pancreatic ductal adenocarcinoma (“PDAC”) that carry an MTAP deletion. The Company will sponsor the clinical trial combination study, and Roche will supply RG6505.

IDE892 was designed to be a potential best-in-class PRMT5 inhibitor and has demonstrated robust monotherapy regressions in MTAP-deleted preclinical models. The Company is evaluating IDE892 in a Phase 1 dose escalation clinical trial in MTAP-deleted solid tumors and plans to initiate Phase 1 combination cohorts, in PDAC with RG6505 as well as in NSCLC and other solid tumors with IDE397, the Company’s proprietary MAT2A inhibitor.

MTAP deletion is estimated to occur in up to 40% of PDAC and almost all MTAP-deleted PDAC harbor co-occurring RAS mutations. Combining a PRMT5 inhibitor with a pan-RAS inhibitor may have the potential to drive deeper and more durable responses for MTAP-deleted PDAC patients who currently have no approved targeted treatment options.

Under the clinical collaboration, the Company and Roche each retain all commercial rights to their respective compounds, including as monotherapy and as combination therapies. There will be a joint governance process between the Company and Roche to oversee the clinical combination study. The clinical collaboration also has the ability to evaluate a combination triplet with IDE892, RG6505, and IDE397, the Company’s Phase 2 MAT2A inhibitor, upon joint approval from both the Company and Roche.

Forward-Looking Statements

Certain statements contained herein are forward-looking statements, including, but not limited to, statements related to (i) the potential therapeutic benefit, safety, and efficacy of IDE892, alone or in combination with RG6505; (ii) the planned clinical development, including the initiation, timing, progress, and design of clinical trials evaluating IDE892 in combination with RG6505 and other agents; (iii) the potential for IDE892 to be a best-in-class PRMT5 inhibitor; (iv) the potential for combination therapies targeting MTAP-deleted and RAS-mutant tumors to drive deeper or more durable responses; (v) the estimated prevalence of MTAP deletions in PDAC; (vi) the potential benefits of the clinical collaboration with Roche; and (vii) the Company’s broader clinical and strategic plans, including the development of its MTAP-deletion portfolio. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks related to the success, cost, and timing of the Company’s product candidate development activities and clinical trials; the risk that results from preclinical studies or early clinical trials may not be predictive of future clinical results; risks related to the development and regulatory approval of drug candidates; risks related to the Company’s dependence on third parties, including Roche, for collaboration activities and clinical supply; risks related to the ability to successfully enroll patients in clinical trials; and risks related to the potential for adverse safety events or lack of efficacy. All forward-looking statements are made as of the date hereof, and the Company undertakes no obligation to update any forward-looking statements to reflect new information, future events, or otherwise, except as required by law. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company’s Annual Report on Form 10-K dated February 17, 2026, the Company’s Quarterly Report on Form 10-Q dated May 5, 2026, and any subsequently filed current and periodic reports filed or furnished with the Securities and Exchange Commission.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    IDEAYA BIOSCIENCES, INC.
Date: June 3, 2026     By:  

/s/ Yujiro Hata

      Yujiro S. Hata
      President and Chief Executive Officer

FAQ

What clinical collaboration did IDEAYA Biosciences (IDYA) announce with Roche?

IDEAYA Biosciences announced a clinical collaboration with Roche to evaluate IDEAYA’s PRMT5 inhibitor IDE892 combined with Roche’s pan-RAS inhibitor RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma, with IDEAYA sponsoring the study and Roche supplying RG6505.

Which cancer types are targeted in the IDEAYA (IDYA) and Roche IDE892 collaboration?

The collaboration focuses on MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA also plans Phase 1 combination cohorts using IDE892 in pancreatic cancer with RG6505 and in non-small cell lung cancer plus other solid tumors together with its MAT2A inhibitor IDE397.

What is IDEAYA’s IDE892 and how is it being developed?

IDE892 is an investigational PRMT5 inhibitor designed as a potential best-in-class therapy. It has shown robust monotherapy regressions in MTAP-deleted preclinical models and is being evaluated in a Phase 1 dose escalation trial in MTAP-deleted solid tumors, including planned combination cohorts.

How common are MTAP deletions in pancreatic ductal adenocarcinoma according to IDEAYA (IDYA)?

IDEAYA states that MTAP deletion is estimated to occur in up to 40% of pancreatic ductal adenocarcinoma cases. The company also notes that almost all MTAP-deleted pancreatic tumors harbor co-occurring RAS mutations, supporting the rationale for combining PRMT5 and pan-RAS inhibitors.

Who retains commercial rights in the IDEAYA (IDYA) and Roche IDE892 clinical collaboration?

Under the collaboration, IDEAYA and Roche each retain all commercial rights to their respective compounds, both as monotherapies and in combination regimens. A joint governance process between the companies will oversee the clinical combination study and any potential triplet regimen decisions.

Could the IDEAYA (IDYA) and Roche collaboration include IDE397 in a triplet regimen?

Yes. The collaboration allows for potential evaluation of a triplet combination of IDE892, RG6505 and IDEAYA’s Phase 2 MAT2A inhibitor IDE397. Any triplet study would require joint approval from both companies and would build on their MTAP-deletion targeting strategy.

Filing Exhibits & Attachments

3 documents